A clinician's response to the oral contraceptive thrombosis controversy

Human Reproduction Update

Volumn 5, Issue 6, 1999, Pages 654-663

  Speroff, L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Clinical practice; Oral contraceptives; Progestins; Thrombosis

Indexed keywords

DESOGESTREL; GESTAGEN; GESTODENE; ORAL CONTRACEPTIVE AGENT;

FEMALE; HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; REVIEW; RISK; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0033378658     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/5.6.654     Document Type: Review

References (83)

1. Adams, M.R., Clarkson, T.B., Koritnik, D.R. and Nash, H.A. (1987) Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil. Steril., 47, 1010-1018.
2. Barrett, D.H., Anda, R.F., Escobedo, L.G. et al. (1994) Trends in oral contraceptive use and cigarette smoking. Arch. Family Med., 3, 438-443.
3. Basdevant, A., Conard, J., Pelissier, C. et al. (1993) Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception, 48, 193-204.
4. Bloemenkammp, K.W.M., Rosendaal, F.R., Helmerhorst, F.M. et al. (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet, 348, 1593-1596.
5. Böttiger, L.E., Boman, G., Eklund, G. and Westerholm, B. (1980) Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet, i, 1097-2001.
6. Brady, W.A., Kritz-Silverstein, D., Barrett-Connor, E. and Morales, A.J. (1998) Prior oral contraceptive use is associated with higher blood pressure in older women. J. Women's Health, 7, 221-227.
7. Burkman, R.T., Robinson, J.C., Kruszon-Moran, D. et al. (1988) Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstet. Gynecol., 71, 33-38.
8. Chasan-Taber, L., Willett, W.C., Manson, J.E. et al. (1996) Prospective study of oral contraceptives and hypertension among women in the United States. Circulation, 94, 483-489.
9. Child, T.J., Rees, M. and MacKenzie, I.Z. (1996) Pregnancy terminations after oral contraception scare. Lancet, 347, 1260-1261.
10. Clarkson, T.B., Adams, M.R., Kaplan, J.R. et al. (1989) From menarche to menopause: coronary artery atherosclerosis and protection in cynomolgus monkeys. Am. J. Obstet. Gynecol., 160, 1280-1285.
11. Clarkson, T.B., Shively, C.A., Morgan, T.M. et al. (1990) Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet. Gynecol., 75, 217-222.
12. Colditz, G.A., and the Nurses' Health Study Research Group (1994) Oral contraceptive use and mortality during 12 years of follow-up: the Nurses' Health Study. Ann. Intern. Med., 120, 821-826.
13. Croft, P. and Hannaford, P.C. (1989) Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. Br. Med. J., 298, 165-168.
14. Darney, P. (1993) Safety and efficacy of a triphasic oral contraceptive containing desogrestrel: results of three multicenter trials. Contraception, 48, 323.
15. de Bruijn, S.F.T.M., Stam, J., Koopman, M.M.W. and Vandenbroucke, J.P., for the Cerebral Venous Sinus Thrombosis Study Group (1998) Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. Br. Med. J., 316, 589-592.
16. Engel, J.H., Engel, E. and Lichtlen, P.R. (1983) Coronary atherosclerosis and myocardial infarction in young women - role of oral contraceptives. Eur. Heart J., 4, 1-8.
17. Fahmy, K., Khairy, M., Allam, G. et al. (1991) Effect of depot-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception, 44, 431.
18. Farmer, R. and Lewis, M. (1996) Oral contraceptives and mortality from venous thromboembolism. Lancet, 348, 1095.
19. Farmer, R.D.T. and Preston, T.D. (1995) The risk of venous thromboembolism associated with low estrogen oral contraceptives. J. Obstet. Gynaecol., 15, 195-200.
20. Farmer, R.D.T., Lawrenson, R.A., Thompson, C.R. et al. (1997) Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet, 349, 83-88.
21. Fruzzetti, F., Ricci, C. and Fioretti, P. (1994) Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception, 49, 579-592.
22. Gerstman, B.B., Piper, J.M., Tomita, D.K. et al. (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol., 133, 32-37.
23. Gevers Leuven, J.A., Dersjant-Roorda, M.C., Helmerhorst, F.M. et al. (1990) Estrogenic effect of gestodene-desogestrel-containing oral contraceptives on lipoprotein metabolism. Am. J. Obstet. Gynecol., 163, 358-362.
24. Heinemann, L.A.J., Lewis, M.A., Assman, A. et al. (1996) Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives? Pharmacoepidemiol. Drug Safety, 5, 285-294.
25. Helmrich, S.P., Rosenberg, L., Kaufman, D.W. et al. (1987) Venous thromboembolism in relation to oral contraceptive use. Obstet. Gynecol., 69, 91-95.
26. Henriksson, P., Stamberger, M., Eriksson, M. et al. (1989) Oestrogen-induced changes in lipoprotein metabolism: role in prevention of atherosclerosis in the cholesterol-fed rabbit. Eur. J. Clin. Invest., 19, 395-403.
27. Hough, J.L. and Zilversmit, D.B. (1986) Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis, 6, 57-63.
28. Jamin, C. and de Mouzon, J. (1996) Selective prescribing of third generation oral contraceptives (OCs). Contraception, 54, 55-56.
29. Jespersen, J., Petersen, K.R. and Skouby, S.O. (1990) Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am. J. Obstet. Gynecol., 163, 396-403.
30. Jick, H., Jick, S.S., Gurewich, V. et al. (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet, 348, 1589-1593.
31. Jugdutt, B.I., Stevens, G.F., Zacks, D.J. et al. (1983) Myocardial infarction, oral contraception, cigarette smoking, and coronary artery spasm in young women. Am. Heart J., 106, 757.
32. Kloosterboer, H.J. and Rekers, H. (1990) Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations. Am. J. Obstet. Gynecol., 163, 370.
33. Kovacs, L., Bartfai, G., Apro, G. et al. (1986) The effect of the contraceptive pill on blood pressure: a randomized controlled trial of three progestogen-oestrogen combinations in Szeged, Hungary. Contraception, 33, 69-77.
34. Kushwaha, R. and Hazzard, W. (1981) Exogenous estrogens attenuate dietary hypercholesterolemia and atherosclerosis in the rabbit. Metabolism, 30, 57-66.
35. Lawson, D.H., Davidson, J.F. and Jick, H. (1977) Oral contraceptive use and venous thromboembolism: absence of an effect of smoking. Br. Med. J., ii, 729-730.
36. LeLorier, J., Grégoire, G., Benhaddad, A. et al. (1997) Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N. Engl. J. Med., 337, 536-542.
37. Lewis, M.A., Heinemann, L.A.J., MacRae, K.D. et al. (1996) The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception, 54, 5-13.
38. Lewis, M.A., Heinemann, L.A.J., Spitzer, W.O. et al. for the Transnational Research Group on Oral Contraceptives and the Health of Young Women (1997a) The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception, 56, 129-140.
39. Lewis, M.A., Spitzer, W.O., Heinemann, L.A.J. et al. (1997b) Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism. Br. Med. J., 315, 679-680.
40. Lidegaard, Ø. (1993) Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. Br. Med. J., 306, 956-963.
41. Lidegaard, Ø. and Edström, B. (1996) Oral contraceptives and myocardial infarction. A case-control study (abstract). Eur. J. Contracept. Reprod. Health Care, 1 (Suppl.), 72-73.
42. Lidegaard, Ø. and Kreiner, S. (1998) Cerebral thrombosis and oral contraceptives. A case-control study. Contraception, 57, 303-314.
43. Lidegaard, Ø., Edstrom, B. and Kreiner, S. (1998) Oral contraceptives and venous thromboembolism. A case-control study. Contraception, 5, 291-301.
44. Martinelli, I., Sacchi, E., Landi, G. et al. (1998) High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N. Engl. J. Med., 338, 1793-1797.
45. Meade, T.W. (1982) Oral contraceptives, clotting factors, and thrombosis. Am. J. Obstet. Gynecol, 142, 758-761.
46. Nichols, M., Robinson, G., Bounds, W. et al. (1993) Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception, 47, 367.
47. Notelovitz, M., Feldmand, E.B., Gillespy, M. and Gudat, J. (1989) Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. Am. J. Obstet. Gynecol., 160, 1269.
48. Notelovitz, M., Kitchens, C.S. and Khan, F.Y. (1992) Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial. Am. J. Obstet. Gynecol., 167, 1255-1261.
49. Pabinger, I., Schneider, B. and the GTH Study Group (1994) Thrombotic risk of women with hereditary antithrombin III, protein C, and protein S deficiency taking oral contraceptive medication. Thromb. Haemost., 5, 548-552.
50. Patsch, W., Brown, S.A., Grotto, A.M., Jr and Young, R.L. (1989) The effect of triphasic oral contraceptives on plasma lipids and lipoproteins. Am. J. Obstet. Gynecol., 161, 1396.
51. Petitti, D.B. (1994) Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. Oxford University Press, New York.
52. Petitti , D.B., Wingerd, J., Pellegrin, F. and Ramcharan, S. (1978) Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am. J. Epidemiol., 108, 480-485.
53. Petitti, D.B., Sidney, S., Bernstein, A. et al. (1996) Stroke in users of low-dose oral contraceptives. N. Engl. J. Med., 335, 8-15.
54. Petitti, D.B., Sidney, S., Quesenberry, C.P., Jr and Bernstein, A. (1997) Incidence of stroke and myocardial infarction in women of reproductive age. Stroke, 28, 280-283.
55. Porter, J.B., Hershel, J. and Walker, A.M. (1987) Mortality among oral contraceptive users. Obstet. Gynecol., 70, 29-32.
56. Pritchard, J.A. and Pritchard, S.A. (1977) Blood pressure response to estrogen-progestin oral contraceptives after pregnancy-induced hypertension. Am. J. Obstet. Gynecol., 129, 733.
57. Qifang, S., Deliang, L., Ziurong, J. et al. (1994) Blood pressure changes and hormonal contraceptives. Contraception, 50, 131.
58. Ridker, P.M., Miletich, J.P., Hennekens, C.H. and Buring, J.E. (1997) Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA, 277, 1305-1307.
59. Rosenberg, L., Hennekens, C.H., Rosner, B. et al. (1980) Oral contraceptive use in relation to nonfatal myocardial infarction. Am. J. Epidemiol., 11, 59-66.
60. Rosenberg, L., Palmer, J.R., Lesko, S.M. and Shapiro, S. (1990) Oral contraceptive use and the risk of myocardial infarction. Am. J. Epidemiol., 131, 1009-1016.
61. Royal College of General Practitioners (1978) Oral contraceptive study: oral contraceptives, venous thrombosis, and varicose veins. J. R. Coll. Gen. Pract., 28, 393-399.
62. Royal College of General Practitioners Oral Contraceptive Study (1983) Incidence of arterial disease among oral contraceptive users. J. R. Coll. Gen. Pract., 33, 75-82.
63. Schlit, A.F., Grandjean, P., Donnez, J. and Lavenne, E. (1995) Large increase in plasmatic 11-dehydro-TXB2 levels due to oral contraceptives. Contraception, 51, 53-58.
64. Shaaban, M.M., Elwan, S.I., El-Kabsh, M.Y. et al. (1984) Effect of levonorgestrel contraceptive implants, Norplant, on bleeding and coagulation. Contraception, 30, 421.
65. Singh, K., Viegas, O.A.C., Koh, S.C.L. and Ratnam, S.S. (1992) Effect of long-term use of Norplant implants on haemostatic function. Contraception, 45, 203.
66. Skjeldestad, F.E. (1997) Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. Contraception, 55, 11-14.
67. Speroff, L. and DeCherney, A. (1993) Evaluation of a new generation of oral contraceptives. Obstet. Gynecol., 81, 1034-1047.
68. Spitzer, W.O., Lewis, M.A., Heinemann, L.A.J. et al. on behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br. Med. J., 312, 83-88.
69. Stampfer, M.J., Willett, W.C., Coldtiz, G.A. et al. (1990) Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am. J. Obstet. Gynecol., 163, 285-291.
70. Suissa, S., Blais, L., Spitzer, W.O. et al. (1997) First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception, 56, 141-146.
71. Thorogood, M., Mann, J., Murphy, M. and Vessey, M. (1992) Risk factors for fatal venous thromboembolism in young women: a case-control study. Int. J. Epidemiol., 21, 48-52.
72. Vandenbroucke, J.P., Koster, T., Briët, E. et al. (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet, 344, 1453-1457.
73. Vandenbroucke, J.P., van der Meer, F.J.M., Helmerhorst, F.M. and Rosendaal, F.R. (1996) Factor V Leiden. Br. Med. J., 313, 1127-1130.
74. Van Lunsen, W.H. (1996) Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third generation progestogens. Eur. J. Contracept. Reprod. Health, 1, 39-45.
75. Vessey, M., Mant, D., Smith, A. and Yeates, D. (1986) Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br. Med. J., 292, 526.
76. Viegas, O.A.C., Koh, S.L.C. and Ratnam, S.S. (1996) The effects of reformulated 2-rod Norplant implant on haemostasis after three years. Contraception, 54, 219-228.
77. Wahl, P., Walden, C., Knopp, R. et al. (1983) Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N. Engl. J. Med., 308, 862.
78. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995a) Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet, 346, 1582-1588.
79. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995b) Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet, 346, 1575-1582.
80. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1996a) Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet, 348, 505-510.
81. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1996b) Ischaemic stroke and combined oral contraceptives: results of an international, multicentre case-control study. Lancet, 348, 498-505.
82. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1997) Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet, 349, 1202-1209.
83. Winkler, U.H., Schindler, A.E., Endrikat, J. and Düsterberg, B. (1996) A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol. Contraception, 53, 75-84.